Psilocybin therapy involves more than the compound itself, and a new research initiative at the University of Southern California is investigating the effects of combining psilocybin with structured mental training.

A team from the Keck School of Medicine of USC, working with the USC Dornsife Brain and Creativity Institute and the USC Norris Comprehensive Cancer Center, has begun the university’s first clinical trial of psychedelic therapy. The study will examine whether structured mindfulness meditation can boost the effects of psilocybin, the active ingredient in psychedelic mushrooms, on mental well-being and cognitive performance.

Funding for the trial comes from ARPA-H’s EVIDENT initiative, a federal program designed to accelerate the development of rapid-acting treatments for mental and behavioral health conditions. The study will investigate whether adding mindfulness training to psilocybin-assisted therapy yields outcomes distinct from those of psilocybin-assisted therapy alone.

A Schedule 1 Drug With a Breakthrough Label

Although the Controlled Substances Act still classifies psilocybin as a Schedule I substance, the FDA has granted it a breakthrough therapy designation for major depressive disorder and treatment-resistant depression. In clinical settings, psilocybin has shown promise in treating these conditions, and other studies suggest it may also help with addiction.

Psilocybin alters a person’s perception, mood, and thought processes, and can influence how individuals experience their senses and their sense of time and space. With therapeutic support, people often report emotionally meaningful or spiritual experiences during these altered states.

Testing Whether Mental Training Changes the Outcome

About 72 middle-aged adults from the Los Angeles area will take part in the study. All participants will have no psychiatric or medical conditions and no previous experience with either psychedelics or meditation. Researchers will assign participants to one of two groups: one will receive supervised psilocybin alone, while the other will receive psilocybin alongside an eight-week mindfulness training program designed to build attention and focus through structured meditation.

The study is based on the hypothesis that mindfulness training, which has demonstrated mental and physical health benefits independently, may enhance the effects of psilocybin-assisted therapy when used together.

“Mindfulness meditation practice provides people with the tools to deconstruct unhelpful narratives, a process that may be amplified by psilocybin-assisted therapy,” said Rael Cahn, MD, PhD, director of the USC Center for Mindfulness Science and the study’s co-lead. The trial, he said, is meant to clarify how combining the two approaches “may enhance both the potential immediate and longer-term effects of psychedelic medicine.”

An Unusually Deep Data Set

The team will collect extensive biological, neurological, and psychological data from participants throughout the study. Participants will undergo EEG scans, brain MRI and fMRI imaging, and provide saliva, blood, and stool samples. Researchers will administer psychological and cognitive assessments before and after treatment and will survey participants again at three, six, and twelve months.

The team will use the data to track changes across psychological, cognitive, neurological, and biological measures, including well-being, spirituality, brain activity, and markers of inflammation and brain health. The open-label design means both participants and researchers are aware of group assignments, which allows for more comprehensive data collection at the expense of some blinding rigor.

Through the EVIDENT initiative, researchers will contribute anonymized trial results to a national repository. The resource will help researchers identify broader patterns in rapid-acting mental health treatments.

“Psilocybin-assisted therapy has the potential to revolutionize how we approach mental health research,” said Caryn Lerman, PhD, director of the USC Norris Comprehensive Cancer Center and the study’s other co-lead. Beyond addiction, she said, there’s growing evidence the treatment could improve “quality of life and emotional well-being for people facing serious illness and end-of-life challenges.”

A Test Case for the Next Wave of Psychedelic Medicine

If mindfulness training is shown to enhance the effects of psilocybin therapy, future protocols for psychedelic treatment may incorporate mental training as an additional component of treatment. Regardless of the outcome, the study will generate one of the most detailed biological and psychological datasets from a psilocybin trial to date.

Whether mindfulness ultimately amplifies psilocybin’s effects remains an open question. By tracking participants’ brains, biology, and psychological well-being over the course of a year, the USC team hopes to generate some of the clearest data yet on how mindset and psychedelic medicine interact.

Austin Burgess is a writer and researcher with a background in sales, marketing, and data analytics. He holds an MBA, a Bachelor of Science in Business Administration, and a data analytics certification. His work focuses on breaking scientific developments, with an emphasis on emerging biology, cognitive neuroscience, and archaeological discoveries.

In recent years, the global landscape of cannabis policy has undergone significant transformations, stirring complex debates about the implications of legalization, decriminalization, and commercial sales on public health and societal well-being. A comprehensive study published in The Lancet Psychiatry on June 17, 2026, provides the most extensive analysis to date of international cannabis policies and their associations with cannabis use, cannabis use disorder, and other psychiatric outcomes. Led by an interdisciplinary team spearheaded by experts from the University of Bath in the UK, this systematic review draws on a wealth of data spanning across continents including the Americas, Europe, Africa, Australia, New Zealand, and Asia, elucidating the nuanced consequences of various regulatory approaches to cannabis.

The study underscores a critical distinction between policy frameworks that decriminalize or tightly regulate cannabis and those that permit large-scale commercial sales. Decriminalization typically involves removing criminal penalties for personal possession while maintaining restrictions on production and distribution. The data shows that such approaches do not generally lead to an uptick in cannabis consumption. Conversely, jurisdictions that have embraced fully commercialized cannabis markets—with broad retail availability and significant profit-driven incentives, such as many US states and Canada—experience higher consumption rates. These markets tend to propel an increase not just in use, but also in cannabis potency and the prevalence of addiction, revealing troubling public health ramifications hitherto underestimated.

Uruguay’s pioneering legalization model exemplifies a tightly regulated framework. Since its inception, Uruguay has implemented strict controls, limiting cannabis products’ availability and potency, distributing through pharmacy networks, cannabis social clubs, and permitting personal cultivation under strict rules. This structure, focused on harm minimization rather than commercial proliferation, correlates with relatively stable cannabis use rates. Such regulatory restraint contrasts sharply with the dynamics in North America, where deregulation has coincided with escalating rates of daily cannabis consumption and a worrying rise in addiction rates. Notably, in the US, the number of daily cannabis consumers now surpasses daily alcohol consumers, a landmark shift underlining the profound public health challenges precipitated by commercial legalization.

The study identifies the expansion of the for-profit cannabis industry as a pivotal factor in increasing health risks. Mirroring patterns observed historically with tobacco and alcohol industries, large-scale cannabis corporations emphasize product innovation, marketing, and aggressive sales strategies. This has catalyzed the availability of increasingly potent cannabis products, which significantly elevates the risk of dependence and the likelihood of adverse psychiatric outcomes, including psychotic disorders. Furthermore, the surge in hospital admissions due to cannabis-related psychosis in regions with commercial cannabis markets casts a serious shadow over the narrative that legalization inherently reduces harm.

In contrast, decriminalization policies appear to offer a more balanced approach, mitigating the harms associated with criminal prosecution—especially in marginalized communities disproportionately affected by enforcement—while not necessarily increasing use. The researchers highlight this as a crucial insight with implications for evolving policy debates, such as those unfolding in the United Kingdom. Here, cannabis remains a Class B controlled substance with severe penalties, although prominent calls for reform, like the 2025 London Drugs Commission report, advocate for shifting possession offenses away from the criminal justice system toward healthcare frameworks, aiming to reduce social and racial inequities.

Medical cannabis, a rapidly expanding sector, emerged as another focal concern within the study. Regulations remain highly inconsistent globally, and often poorly governed, raising critical questions about safety and therapeutic efficacy. The evidence base, as reviewed in the study, remains inconclusive or limited for many medical indications, especially psychiatric disorders. Despite increasing prescriptions of cannabinoids to treat conditions such as insomnia, autism traits, or substance use disorders, outcomes from randomized clinical trials suggest only modest benefits and lack robust evidence to support claims for efficacy in anxiety, PTSD, depression, or psychosis management. Moreover, unregulated medical cannabis access may inadvertently increase risks of harm due to insufficient clinical oversight and dosage control.

A significant aspect of the analysis relates to cannabis’ psychiatric implications beyond addiction. While daily use has been found to synergistically interact with other risk factors to elevate psychosis risk, the associations with depression, anxiety, and suicidality remain equivocal and warrant further investigation. This nuanced understanding challenges oversimplified narratives around cannabis as either categorically harmful or benign and underscores the critical need for targeted, evidence-based public health interventions.

Professor Tom Freeman, lead author from the University of Bath’s Department of Psychology, emphasizes the decisive role of policy modality over the mere presence of policy changes. He asserts that decriminalization or strict legal regulation can disentangle the harms of criminalization from those stemming from increased cannabis availability and potency. By contrast, commercialized legalization prioritizes market expansion, often at the expense of public health safeguards, exacerbating addiction, and psychiatric morbidity.

The research team also notes a geographical research gap, as much existing evidence centers on North America. They advocate for expanded studies in diverse contexts to fully capture the global ramifications of shifting cannabis policies. Such comprehensive surveillance is vital as an increasing number of countries contemplate or implement reforms, thus influencing future public health trajectories internationally.

The robustness of the conclusions stems from the study’s systematic review methodology, synthesizing findings from numerous epidemiological investigations, clinical trials, and policy analyses. This integrative approach provides a panoramic yet detailed picture of cannabis policy consequences, supporting evidence-based policymaking in a politically charged and rapidly evolving arena.

As cannabis policies continue to evolve worldwide, this landmark study serves as a clarion call for caution, nuanced regulation, and rigorous scientific evaluation. In balancing decriminalization and legal regulation against the risks posed by unbridled commercial markets, policymakers face complex trade-offs with profound implications for population health and social justice.

Subject of Research: Cannabis policies and their effects on cannabis use, addiction, and psychiatric disorders in human populations.

Article Title: International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders published in The Lancet Psychiatry

News Publication Date: 17-Jun-2026

Web References:
The Lancet Psychiatry Article

References:
Systematic review published in The Lancet Psychiatry, 2026

Keywords: Cannabis policy, legalization, decriminalization, cannabis addiction, psychosis, psychiatric disorders, commercial cannabis markets, public health, medical cannabis, cannabis potency, substance use disorder

In a small randomized trial in the United Kingdom, adults who added a serving of 100% fruit juice or a smoothie to a healthier diet reported lower depression scores after four weeks.

The post Daily Glass of Fruit Juice May Lift Your Mood: Study appeared first on Sci.News: Breaking Science News.